Refractory Small Lymphocytic Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +9 more
2022-04-07
Apr 7, 2022
N
Active, not recruiting
  • Recurrent B-Cell Prolymphocytic Leukemia
  • +5 more
  • Palo Alto, California
  • +2 more
2022-04-05
Apr 5, 2022
N
Active, not recruiting
  • Ann Arbor Stage III Small Lymphocytic Lymphoma
  • +7 more
  • Washington, District of Columbia
  • +1 more
2022-04-05
Apr 5, 2022
F
Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022
M
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-15
Mar 15, 2022
M
Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic
2022-03-25
Mar 25, 2022
M
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +4 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
2022-03-22
Mar 22, 2022
M
Not yet recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-03
Mar 3, 2022
F
Recruiting
  • Acute Leukemia
  • +18 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
N
Suspended
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +25 more
  • Birmingham, Alabama
  • +23 more
2022-03-05
Mar 5, 2022
C
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CpG-STAT3 siRNA CAS3/SS3
  • Radiation Therapy
  • Duarte, California
    City of Hope Medical Center
2022-02-28
Feb 28, 2022
F
Completed
  • CD19-Positive Neoplastic Cells Present
  • +12 more
  • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-08
Feb 8, 2022
M
Not yet recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +6 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2022-02-18
Feb 18, 2022
O
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +58 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
2022-02-16
Feb 16, 2022
M
Active, not recruiting
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-09
Feb 9, 2022
F
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-01-24
Jan 24, 2022
J
Recruiting
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-12-17
Dec 17, 2021
V
Withdrawn
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Dose combination 1-1
  • +5 more
  • (no location specified)
2021-11-01
Nov 1, 2021
S
Completed
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duarte, California
  • +1 more
2021-09-01
Sep 1, 2021
C
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duarte, California
  • +2 more
2021-08-13
Aug 13, 2021
J
Recruiting
  • CD19 Positive
  • +13 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
2021-08-10
Aug 10, 2021